• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极罕见的皮肤顶泌汗腺癌中DNA修复靶向分析

analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

作者信息

Mäkelä Rami, Härmä Ville, Badra Fajardo Nibal, Wells Greg, Lygerou Zoi, Sangfelt Olle, Kononen Juha, Rantala Juha K

机构信息

Misvik Biology Oy, Turku, Finland.

University of Sheffield, Department of Oncology and Metabolism, Sheffield, UK.

出版信息

Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961.

DOI:10.18632/oncotarget.27961
PMID:34084283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8169071/
Abstract

Cutaneous apocrine carcinoma is an extreme rare malignancy derived from a sweat gland. Histologically sweat gland cancers resemble metastatic mammary apocrine carcinomas, but the genetic landscape remains poorly understood. Here, we report a rare metastatic case with a aberration identified previously as a familial susceptibility gene for breast cancer in the Finnish population. As PALB2 exhibits functions in the BRCA1/2-RAD51-dependent homologous DNA recombination repair pathway, we sought to use functional screening to explore sensitivity of the tumor cells to therapeutic targeting of DNA repair. Drug screening suggested sensitivity of the PALB2 deficient cells to BET-bromodomain inhibition, and modest sensitivity to DNA-PKi, ATRi, WEE1i and PARPi. A phenotypic RNAi screen of 300 DNA repair genes was undertaken to assess DNA repair targeting in more detail. Core members of the HR and MMEJ pathways were identified to be essential for viability of the cells. RNAi inhibition of RAD52-dependent HR on the other hand potentiated the efficacy of a novel BETi ODM-207. Together these results describe the first ever CAC case with a BRCAness genetic background, evaluate combinatorial DNA repair targeting, and provide a data resource for further analyses of DNA repair targeting in PALB2 deficient cancers.

摘要

皮肤大汗腺癌是一种极其罕见的源自汗腺的恶性肿瘤。从组织学上看,汗腺癌类似于转移性乳腺大汗腺癌,但对其基因图谱仍知之甚少。在此,我们报告了一例罕见的转移病例,其中存在一种在芬兰人群中先前被确定为乳腺癌家族易感性基因的畸变。由于PALB2在BRCA1/2-RAD51依赖的同源DNA重组修复途径中发挥作用,我们试图通过功能筛选来探索肿瘤细胞对DNA修复治疗靶点的敏感性。药物筛选表明,PALB2缺陷细胞对BET-溴结构域抑制敏感,对DNA-PKi、ATRi、WEE1i和PARPi有适度敏感性。对300个DNA修复基因进行了表型RNAi筛选,以更详细地评估DNA修复靶点。HR和MMEJ途径的核心成员被确定对细胞活力至关重要。另一方面,RNAi抑制RAD52依赖的HR增强了新型BETi ODM-207的疗效。这些结果共同描述了首例具有BRCAness基因背景的皮肤大汗腺癌病例,评估了联合DNA修复靶点,并为进一步分析PALB2缺陷癌症中的DNA修复靶点提供了数据资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/a7e2f85cbf42/oncotarget-12-1100-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/88265f32feb0/oncotarget-12-1100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/0db14a5c333f/oncotarget-12-1100-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/1c501c45fa11/oncotarget-12-1100-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/a7e2f85cbf42/oncotarget-12-1100-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/88265f32feb0/oncotarget-12-1100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/0db14a5c333f/oncotarget-12-1100-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/1c501c45fa11/oncotarget-12-1100-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1dd/8169071/a7e2f85cbf42/oncotarget-12-1100-g004.jpg

相似文献

1
analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.极罕见的皮肤顶泌汗腺癌中DNA修复靶向分析
Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961.
2
Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.杂合性PALB2基因c.1592delT突变使乳腺癌患者的DNA双链断裂修复进入易出错途径。
Oncogene. 2016 Jul 21;35(29):3796-806. doi: 10.1038/onc.2015.448. Epub 2015 Dec 7.
3
Therapeutic exploitation of tumor cell defects in homologous recombination.同源重组中肿瘤细胞缺陷的治疗性利用。
Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267.
4
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.BET 抑制剂 INCB054329 降低卵巢癌细胞中同源重组效率并增强 PARP 抑制剂的活性。
Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.
5
PALB2 (partner and localizer of BRCA2).PALB2(乳腺癌2号基因的伙伴和定位蛋白)
Atlas Genet Cytogenet Oncol Haematol. 2018 Apr;22(12):484-490. doi: 10.4267/2042/69016.
6
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.BET 蛋白调控同源重组介导的 DNA 修复:BRCA 样特征及其对癌症治疗的影响。
Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
7
[The so-called sweat-gland carcinoma of the human breast. A review (author's transl)].[所谓的人类乳腺汗腺癌。综述(作者译)]
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Jan 21;88(2):105-19. doi: 10.1007/BF00284119.
8
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.DNA修复基因的双等位基因改变是乳腺癌中同源重组DNA修复缺陷的基础。
J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.
9
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.家族性胰腺癌的小鼠模型:Palb2、Brca1 和 Brca2 基因突变小鼠系中肿瘤的组织病理学、潜伏期和药物敏感性。
PLoS One. 2019 Dec 26;14(12):e0226714. doi: 10.1371/journal.pone.0226714. eCollection 2019.
10
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.PALB2在DNA损伤反应及癌症易感性中的作用
Int J Mol Sci. 2017 Aug 31;18(9):1886. doi: 10.3390/ijms18091886.

引用本文的文献

1
Exploring the Potential of Homologous Recombination Protein PALB2 in Synthetic Lethal Combinations.探索同源重组蛋白PALB2在合成致死组合中的潜力。
ACS Chem Biol. 2025 May 16;20(5):1099-1106. doi: 10.1021/acschembio.5c00111. Epub 2025 Apr 29.
2
Exome sequencing reveals biallelic inactivation of in cutaneous apocrine carcinoma: A case report and review of the literature.外显子组测序揭示皮肤大汗腺癌中[具体基因]的双等位基因失活:一例病例报告及文献复习
JAAD Case Rep. 2024 Apr 25;49:47-50. doi: 10.1016/j.jdcr.2024.04.025. eCollection 2024 Jul.
3
Precision oncology using ex vivo technology: a step towards individualised cancer care?

本文引用的文献

1
Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy.利用微同源介导的末端连接通路进行癌症治疗。
Cancer Res. 2020 Nov 1;80(21):4593-4600. doi: 10.1158/0008-5472.CAN-20-1672. Epub 2020 Jul 10.
2
Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma.在罕见的转移性上皮-肌上皮癌中进行靶向治疗的离体评估。
Neoplasia. 2020 Sep;22(9):390-398. doi: 10.1016/j.neo.2020.06.007. Epub 2020 Jul 6.
3
PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.
使用体外技术的精准肿瘤学:迈向个体化癌症治疗的一步?
Expert Rev Mol Med. 2022 Oct 3;24:e39. doi: 10.1017/erm.2022.32.
PTEN 和 DNA-PK 决定了人乳腺癌对 WEE1 抑制的敏感性和恢复能力。
Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894.
4
Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.在罕见的转移性脐尿管癌中进行药物疗效的离体模型构建。
BMC Cancer. 2020 Jun 23;20(1):590. doi: 10.1186/s12885-020-07092-w.
5
Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma.基于图像的体外药物筛选以评估复发性胸腺瘤的靶向治疗
Lung Cancer. 2020 Jul;145:27-32. doi: 10.1016/j.lungcan.2020.04.036. Epub 2020 May 4.
6
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors.使用溴结构域和额外末端结构域(BET)抑制剂及丝裂原活化蛋白激酶(MEK)抑制剂靶向治疗表达MYCN的三阴性乳腺癌
Sci Transl Med. 2020 Mar 11;12(534). doi: 10.1126/scitranslmed.aaw8275.
7
Microcystic adnexal carcinoma: report of rare cases.微囊性附属器癌:罕见病例报告。
Biosci Rep. 2020 Jan 31;40(1). doi: 10.1042/BSR20191557.
8
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.一种有治疗作用的联合癌症疗法通过低交叉耐药性和药物协同作用实现高分数细胞杀伤。
Elife. 2019 Nov 19;8:e50036. doi: 10.7554/eLife.50036.
9
A clinical, pathological and immunohistochemical series of 9 cases of primary cutaneous apocrine carcinomas of the head and neck.一项关于头颈部原发性皮肤大汗腺癌的临床、病理和免疫组织化学系列研究,共纳入 9 例病例。
Australas J Dermatol. 2020 May;61(2):e189-e195. doi: 10.1111/ajd.13199. Epub 2019 Nov 17.
10
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.RAD52作为基于合成致死性的抗癌疗法的潜在靶点。
Cancers (Basel). 2019 Oct 14;11(10):1561. doi: 10.3390/cancers11101561.